CN103690483A - Dl-praeruptorin A microemulsion and preparation method thereof - Google Patents
Dl-praeruptorin A microemulsion and preparation method thereof Download PDFInfo
- Publication number
- CN103690483A CN103690483A CN201310726365.8A CN201310726365A CN103690483A CN 103690483 A CN103690483 A CN 103690483A CN 201310726365 A CN201310726365 A CN 201310726365A CN 103690483 A CN103690483 A CN 103690483A
- Authority
- CN
- China
- Prior art keywords
- oil
- microemulsion
- emulsifier
- proscitin
- praeruptorin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000004530 micro-emulsion Substances 0.000 title claims abstract description 64
- 238000002360 preparation method Methods 0.000 title claims abstract description 25
- 238000000593 microemulsion method Methods 0.000 title description 4
- XGPBRZDOJDLKOT-CCGSVPMNSA-N [(9r,10r)-10-acetyloxy-8,8-dimethyl-2-oxo-9,10-dihydropyrano[2,3-f]chromen-9-yl] (e)-2-methylbut-2-enoate Chemical compound C1=CC(=O)OC2=C1C=CC1=C2[C@@H](OC(C)=O)[C@@H](OC(=O)C(/C)=C/C)C(C)(C)O1 XGPBRZDOJDLKOT-CCGSVPMNSA-N 0.000 title 1
- 239000003921 oil Substances 0.000 claims abstract description 31
- 239000000203 mixture Substances 0.000 claims abstract description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 12
- 239000007957 coemulsifier Substances 0.000 claims abstract description 7
- 239000003995 emulsifying agent Substances 0.000 claims abstract description 7
- 235000019198 oils Nutrition 0.000 claims description 30
- -1 Span Polymers 0.000 claims description 18
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical group CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 14
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 9
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 9
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims description 6
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims description 6
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims description 6
- 239000005642 Oleic acid Substances 0.000 claims description 6
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims description 6
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims description 6
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 6
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 claims description 5
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 5
- 239000002202 Polyethylene glycol Substances 0.000 claims description 5
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 claims description 5
- 150000003904 phospholipids Chemical class 0.000 claims description 5
- 229920001223 polyethylene glycol Polymers 0.000 claims description 5
- 229920000136 polysorbate Polymers 0.000 claims description 5
- BBMCTIGTTCKYKF-UHFFFAOYSA-N 1-heptanol Chemical compound CCCCCCCO BBMCTIGTTCKYKF-UHFFFAOYSA-N 0.000 claims description 4
- KBPLFHHGFOOTCA-UHFFFAOYSA-N caprylic alcohol Natural products CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 claims description 4
- 238000004945 emulsification Methods 0.000 claims description 4
- 239000004006 olive oil Substances 0.000 claims description 4
- 235000008390 olive oil Nutrition 0.000 claims description 4
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 claims description 4
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims description 3
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 3
- 229960000502 poloxamer Drugs 0.000 claims description 3
- 229920001983 poloxamer Polymers 0.000 claims description 3
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 3
- 239000008348 synthetic phosphatidyl choline Substances 0.000 claims description 3
- AMEMLELAMQEAIA-UHFFFAOYSA-N 6-(tert-butyl)thieno[3,2-d]pyrimidin-4(3H)-one Chemical compound N1C=NC(=O)C2=C1C=C(C(C)(C)C)S2 AMEMLELAMQEAIA-UHFFFAOYSA-N 0.000 claims description 2
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 claims description 2
- SHBUUTHKGIVMJT-UHFFFAOYSA-N Hydroxystearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OO SHBUUTHKGIVMJT-UHFFFAOYSA-N 0.000 claims description 2
- 239000004698 Polyethylene Substances 0.000 claims description 2
- 235000019485 Safflower oil Nutrition 0.000 claims description 2
- 229930006000 Sucrose Natural products 0.000 claims description 2
- 229940099418 d- alpha-tocopherol succinate Drugs 0.000 claims description 2
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 2
- FMMOOAYVCKXGMF-MURFETPASA-N ethyl linoleate Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(=O)OCC FMMOOAYVCKXGMF-MURFETPASA-N 0.000 claims description 2
- 229940031016 ethyl linoleate Drugs 0.000 claims description 2
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 claims description 2
- 229940093471 ethyl oleate Drugs 0.000 claims description 2
- 229930195729 fatty acid Natural products 0.000 claims description 2
- 239000000194 fatty acid Substances 0.000 claims description 2
- 229940072106 hydroxystearate Drugs 0.000 claims description 2
- 229940033357 isopropyl laurate Drugs 0.000 claims description 2
- 229940074928 isopropyl myristate Drugs 0.000 claims description 2
- 229940075495 isopropyl palmitate Drugs 0.000 claims description 2
- FMMOOAYVCKXGMF-UHFFFAOYSA-N linoleic acid ethyl ester Natural products CCCCCC=CCC=CCCCCCCCC(=O)OCC FMMOOAYVCKXGMF-UHFFFAOYSA-N 0.000 claims description 2
- 229960002969 oleic acid Drugs 0.000 claims description 2
- 150000008105 phosphatidylcholines Chemical class 0.000 claims description 2
- 229920000573 polyethylene Polymers 0.000 claims description 2
- 235000005713 safflower oil Nutrition 0.000 claims description 2
- 239000003813 safflower oil Substances 0.000 claims description 2
- 239000003549 soybean oil Substances 0.000 claims description 2
- 235000012424 soybean oil Nutrition 0.000 claims description 2
- 239000005720 sucrose Substances 0.000 claims description 2
- 239000004359 castor oil Substances 0.000 claims 4
- 235000019438 castor oil Nutrition 0.000 claims 4
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims 4
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 claims 2
- 239000010495 camellia oil Substances 0.000 claims 2
- 235000019483 Peanut oil Nutrition 0.000 claims 1
- 235000005687 corn oil Nutrition 0.000 claims 1
- 239000002285 corn oil Substances 0.000 claims 1
- 235000012343 cottonseed oil Nutrition 0.000 claims 1
- 239000002385 cottonseed oil Substances 0.000 claims 1
- 239000008344 egg yolk phospholipid Substances 0.000 claims 1
- 229940068998 egg yolk phospholipid Drugs 0.000 claims 1
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 claims 1
- 239000001087 glyceryl triacetate Substances 0.000 claims 1
- 235000013773 glyceryl triacetate Nutrition 0.000 claims 1
- 239000000944 linseed oil Substances 0.000 claims 1
- 235000021388 linseed oil Nutrition 0.000 claims 1
- 229940057917 medium chain triglycerides Drugs 0.000 claims 1
- TVMXDCGIABBOFY-UHFFFAOYSA-N n-Octanol Natural products CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 claims 1
- 229940042880 natural phospholipid Drugs 0.000 claims 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims 1
- 239000000312 peanut oil Substances 0.000 claims 1
- 239000008159 sesame oil Substances 0.000 claims 1
- 235000011803 sesame oil Nutrition 0.000 claims 1
- 229940083466 soybean lecithin Drugs 0.000 claims 1
- 239000008347 soybean phospholipid Substances 0.000 claims 1
- 229960002622 triacetin Drugs 0.000 claims 1
- XGPBRZDOJDLKOT-YRCPKEQFSA-N [(9r,10r)-10-acetyloxy-8,8-dimethyl-2-oxo-9,10-dihydropyrano[2,3-f]chromen-9-yl] (z)-2-methylbut-2-enoate Chemical compound C1=CC(=O)OC2=C1C=CC1=C2[C@@H](OC(C)=O)[C@@H](OC(=O)C(\C)=C/C)C(C)(C)O1 XGPBRZDOJDLKOT-YRCPKEQFSA-N 0.000 abstract description 20
- 239000003814 drug Substances 0.000 abstract description 17
- 229940079593 drug Drugs 0.000 abstract description 10
- 238000010521 absorption reaction Methods 0.000 abstract description 4
- 208000024172 Cardiovascular disease Diseases 0.000 abstract description 3
- 208000029078 coronary artery disease Diseases 0.000 abstract description 3
- 238000011068 loading method Methods 0.000 abstract description 3
- 206010040880 Skin irritation Diseases 0.000 abstract description 2
- 230000002265 prevention Effects 0.000 abstract description 2
- 230000036556 skin irritation Effects 0.000 abstract description 2
- 231100000475 skin irritation Toxicity 0.000 abstract description 2
- 230000035699 permeability Effects 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- XGPBRZDOJDLKOT-CIRUDOSSSA-N [(9r,10s)-10-acetyloxy-8,8-dimethyl-2-oxo-9,10-dihydropyrano[2,3-f]chromen-9-yl] (z)-2-methylbut-2-enoate Chemical compound C1=CC(=O)OC2=C1C=CC1=C2[C@H](OC(C)=O)[C@@H](OC(=O)C(\C)=C/C)C(C)(C)O1 XGPBRZDOJDLKOT-CIRUDOSSSA-N 0.000 description 38
- XGPBRZDOJDLKOT-UHFFFAOYSA-N praeruptorin A Natural products C1=CC(=O)OC2=C1C=CC1=C2C(OC(C)=O)C(OC(=O)C(C)=CC)C(C)(C)O1 XGPBRZDOJDLKOT-UHFFFAOYSA-N 0.000 description 37
- 239000012071 phase Substances 0.000 description 19
- 238000001914 filtration Methods 0.000 description 8
- 239000002245 particle Substances 0.000 description 8
- ZEMPKEQAKRGZGQ-AAKVHIHISA-N 2,3-bis[[(z)-12-hydroxyoctadec-9-enoyl]oxy]propyl (z)-12-hydroxyoctadec-9-enoate Chemical compound CCCCCCC(O)C\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CC(O)CCCCCC)COC(=O)CCCCCCC\C=C/CC(O)CCCCCC ZEMPKEQAKRGZGQ-AAKVHIHISA-N 0.000 description 7
- 230000005540 biological transmission Effects 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 244000068988 Glycine max Species 0.000 description 3
- 235000010469 Glycine max Nutrition 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 229960004756 ethanol Drugs 0.000 description 3
- 230000035515 penetration Effects 0.000 description 3
- 210000000582 semen Anatomy 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- 102000004328 Cytochrome P-450 CYP3A Human genes 0.000 description 2
- 108010081668 Cytochrome P-450 CYP3A Proteins 0.000 description 2
- QXKHYNVANLEOEG-UHFFFAOYSA-N Methoxsalen Chemical compound C1=CC(=O)OC2=C1C=C1C=COC1=C2OC QXKHYNVANLEOEG-UHFFFAOYSA-N 0.000 description 2
- 241001597008 Nomeidae Species 0.000 description 2
- 241001254606 Peucedanum praeruptorum Species 0.000 description 2
- 229920002690 Polyoxyl 40 HydrogenatedCastorOil Polymers 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- PCWZKQSKUXXDDJ-UHFFFAOYSA-N Xanthotoxin Natural products COCc1c2OC(=O)C=Cc2cc3ccoc13 PCWZKQSKUXXDDJ-UHFFFAOYSA-N 0.000 description 2
- 230000001476 alcoholic effect Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000004064 cosurfactant Substances 0.000 description 2
- 229960000935 dehydrated alcohol Drugs 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 230000001804 emulsifying effect Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000010579 first pass effect Methods 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 229960004469 methoxsalen Drugs 0.000 description 2
- SQBBOVROCFXYBN-UHFFFAOYSA-N methoxypsoralen Natural products C1=C2OC(=O)C(OC)=CC2=CC2=C1OC=C2 SQBBOVROCFXYBN-UHFFFAOYSA-N 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 1
- JGSARLDLIJGVTE-UHFFFAOYSA-N 3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-UHFFFAOYSA-N 0.000 description 1
- 241000510531 Angelica decursiva Species 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 241000125183 Crithmum maritimum Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 241000244269 Peucedanum Species 0.000 description 1
- 229940127315 Potassium Channel Openers Drugs 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000009692 acute damage Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 239000000924 antiasthmatic agent Substances 0.000 description 1
- 239000003434 antitussive agent Substances 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 208000015606 cardiovascular system disease Diseases 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 238000005189 flocculation Methods 0.000 description 1
- 230000016615 flocculation Effects 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000002932 luster Substances 0.000 description 1
- 239000012982 microporous membrane Substances 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000013441 quality evaluation Methods 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 210000004003 subcutaneous fat Anatomy 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000013271 transdermal drug delivery Methods 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
Images
Landscapes
- Medicinal Preparation (AREA)
Abstract
白花前胡甲素微乳及其制备方法，涉及白花前胡甲素微乳。所述白花前胡甲素微乳按质量百分比的组成为：白花前胡甲素0.1%～0.8%；油5%～10%；乳化剂10%～16.67%；助乳化剂20%～33.33%；余量为水。将白花前胡甲素、油、乳化剂、助乳化剂混合得油相，将水加到油相中，混匀乳化即得白花前胡甲素微乳。采用生物相容性好的辅料，将难溶性药物Pd-Ia制成O/W微乳，改善了Pd-Ia的溶解度，提高药物的稳定性与载药量，增加药物透皮吸收。所制备的白花前胡甲素微乳经皮渗透性好、对皮肤刺激性小、制备工艺简单、成本低、质量稳定。在心血管疾病，特别是冠心病的临床治疗及预防作用。The prosaltin microemulsion and the preparation method thereof relate to the prosaltin microemulsion. The composition of the described proscitin microemulsion by mass percentage is: 0.1%～0.8% of proscitin; 5%～10% of oil; 10%～16.67% of emulsifier; 20%～33.33% of co-emulsifier; water. Mix proscitin, oil, emulsifier, and co-emulsifier to obtain an oil phase, add water to the oil phase, mix and emulsify to obtain a microemulsion of proscitin. Using excipients with good biocompatibility, the insoluble drug Pd-Ia is made into O/W microemulsion, which improves the solubility of Pd-Ia, improves the stability and drug loading of the drug, and increases the transdermal absorption of the drug. The prepared proscitin microemulsion has good transdermal permeability, little skin irritation, simple preparation process, low cost and stable quality. In the clinical treatment and prevention of cardiovascular diseases, especially coronary heart disease.
Description
Technical field
The present invention relates to praeruptorin A microemulsion, especially relate to a kind of praeruptorin A microemulsion and preparation method thereof.
Background technology
Praeruptorin A is a kind of angle-pyrancoumarins extracting from xanthotoxin, and chemical name is 3 '-Radix Angelicae Sinensis acyloxy-4 '-acetyl group-3 ', 4 '-bis-hydrogen amyrolins, and structural formula is as follows:
Molecular weight: 386.
Chinese medicine Radix Peucedani is the dry root of samphire Peucedanum praeruptorum DUNN (Peucedanum praeruptrum Dunn) or RADIX PEUCEDANI (P.decursivum maxim), there is loose wind heat clearing away, the effect of lowering the adverse-rising QI to resolve phlegm, as antitussive and antiasthmatic drugs and extensive use.A kind of angle-pyrancoumarins of praeruptorin A (dl-praeruptorin A, Pd-Ia) for extracting in xanthotoxin, is the main effective ingredient of Peucedanum praeruptorum DUNN, and the tip-like that is white in color crystallization is fat-soluble, is soluble in organic solvent.
Pharmacological research shows in recent years, and Pd-Ia, as a kind of calcium channel blocker and potassium channel openers, has the effect of Ischemic myocardium and focal cerebral ischemia acute injury; Pd-Ia can be used as a kind of newtype drug, and the clinical treatment of cardiovascular and respiratory system disease, particularly coronary heart disease and prevention are had to potential and wide application prospect.Have the advantages that dosage is little, evident in efficacy, toxic and side effects is little.
Research discovery, Pd-Ia oral administration may be by the CYP3A metabolism in gastrointestinal tract or liver, and first pass effect is strong, and in liver, mainly by CYP3A catalysis, metabolism, the half-life is short.Oral administration does not reach therapeutic purposes, but drug administration by injection, and patient's compliance is poor and cause the problems such as wound.Therefore, Pd-Ia is prepared into transdermal administration, at present relevant praeruptorin A microemulsion Percutaneously administrable preparation there is not yet relevant report.
Microemulsion is to be mixed in the proper ratio and spontaneous a kind of transparent, low-viscosity, the isotropism forming and thermodynamically stable dispersion by water, oil phase, surfactant and cosurfactant.The particle diameter of microemulsion, generally at 10～100nm, is evenly distributed, and can make inclusive medicine dispersion improve, thereby promotes the Transdermal absorption of medicine.Microemulsion has good dissolubility to lipotropy and hydrophilic medicament, has the higher compatibility with cuticular intercellular lipid bilayer, can penetrate horny layer and enter body circulation and the effect of performance whole body therapeutic; The special tectonic of microemulsion drop, the pharmaceutical release time after percutaneous dosing is longer, and blood drug level is more steady.Microemulsion has as a kind of novel drug-supplying system that good stability, solvability are strong, preparation is simple and easy to the advantages such as industrialization, the sterilizing of available filtration method.Over nearly 20 years, microemulsion is in the research of the multiple route of administration such as transdermal, oral, injection, mucosa delivery.Aspect transdermal drug delivery system, the application of microemulsion is more and more extensive, compares with hydrogel, Emulsion, suspensoid etc., has higher drug loading and the transdermal capability of Geng Gao.Therefore, the carrier of microemulsion Chang Zuowei percutaneous dosing.
Summary of the invention
The object of this invention is to provide a kind of praeruptorin A microemulsion and preparation method thereof.
By mass percentage composed as follows of described praeruptorin A microemulsion:
Surplus is water.
Described oil can be selected from least one in ethyl oleate, isopropyl myristate, isopropyl palmitate, oleic acid, isopropyl laurate, three sad certain herbaceous plants with big flowers acid glycerides, medium chain triglyceride, Ethyl linoleate, soybean oil, Oleum Ricini, Semen Maydis oil, olive oil, Oleum Arachidis hypogaeae semen, safflower oil, Semen Lini oil, Oleum Gossypii semen, Oleum sesami, Oleum Camelliae etc., preferably at least one in isopropyl myristate, isopropyl palmitate, oleic acid, Oleum Camelliae, Fructus Canarii albi wet goods.
Described emulsifying agent is optional from tween, span, poloxamer, phospholipid of natural soybean, natural yolk phospholipid, native phosphatidylcholine, native phosphatidylcholine derivant, semi-synthetic phosphatidylcholine, semi-synthetic derivative of phosphatidylcholine, Myrj 45, sucrose fatty acid ester, Polyethylene Glycol-vitamin e succinate, PEG-DSPE, polyethylene glycol hydroxystearate, polyoxyethylene hydrogenated Oleum Ricini, at least one in polyoxyethylene hydrogenated Oleum Ricini derivant etc., preferred polyoxyethylene hydrogenated Oleum Ricini, tween, at least one in phospholipid of natural soybean etc.
Described co-emulsifier can be selected from least one in ethanol, propylene glycol, normal propyl alcohol, glycerol, n-butyl alcohol, n-octyl alcohol, n-heptanol, carbitol, Polyethylene Glycol, triacetyl glycerine etc., at least one in preferred alcohol, propylene glycol etc.
The preparation method of described praeruptorin A microemulsion is as follows:
Praeruptorin A, oil, emulsifying agent, co-emulsifier are mixed to get to oil phase, water is added in oil phase, mix emulsifying and obtain praeruptorin A microemulsion.
Describedly mix emulsifying and can adopt high pressure homogenize emulsion process or supersound method etc.
Prepared praeruptorin A microemulsion, its outward appearance is colourless translucent colloid substance, and average viscosity is 2706mPas, and viscosity is moderate, and pH value is 5.0～8.0, shows that microemulsion structure in gel keeps good, good stability under transmission electron microscope.
For fear of first pass effect, heighten the effect of a treatment, improve patient's compliance, facilitate clinical application, the present invention has adopted the adjuvant of good biocompatibility, first insoluble drug Pd-Ia is made to O/W microemulsion, has improved the dissolubility of Pd-Ia, improve stability and the drug loading of medicine, increase the Transdermal absorption of medicine.
The prepared praeruptorin A microemulsion of the present invention has the advantages such as percutaneous permeation is good, little to skin irritation, preparation technology is simple, cost is low, steady quality.As a kind of newtype drug, in cardiovascular disease, the particularly clinical treatment of coronary heart disease and preventive effect.
Accompanying drawing explanation
Fig. 1 is the cumulative in vitro transdermal penetration curve (n=5) of the embodiment of the present invention 1 praeruptorin A microemulsion and reference preparation (saturated oils acid solution, 33% alcoholic solution); Curve A is embodiment 1, and curve B is 33% alcoholic solution, and curve C is saturated oils acid solution.
Fig. 2 is the praeruptorin A microemulsion transmission electron microscope picture (* 25000) of the embodiment of the present invention 1 preparation, and in Fig. 2, scale is 100nm.
Fig. 3 is that the praeruptorin A microemulsion of the embodiment of the present invention 1 preparation is placed the transmission electron microscope picture of 0 month in room temperature, and in Fig. 3, scale is 100nm.
Fig. 4 is that the praeruptorin A microemulsion of the embodiment of the present invention 1 preparation is placed the transmission electron microscope picture after 6 months in room temperature, and in Fig. 4, scale is 100nm.
The specific embodiment
The present invention is further illustrated in connection with accompanying drawing for following examples.
Embodiment 1 praeruptorin A microemulsion, its formula is composed as follows:
Preparation method: oleic acid, polyoxyethylene hydrogenated Oleum Ricini (Cremophor RH40), dehydrated alcohol mix homogeneously are obtained to oil phase, praeruptorin A is added in oil phase and dissolved completely; The oil phase that contains praeruptorin A is at room temperature stirred to 10min and make it mix homogeneously, gradually water is added again, at the airtight middle continuous stirring 10min of room temperature, last ultrasonic 5min, after the 0.22 μ m microporous filter membrane aseptic filtration of footpath, obtain colourless translucent praeruptorin A microemulsion.
Preparation method: by isopropyl myristate, poloxamer, the even oil phase that obtains of mixed with propylene glycol, praeruptorin A is added in oil phase and dissolved completely; The oil phase that contains praeruptorin A is at room temperature stirred to 10min and make it mix homogeneously, gradually water is added again, at the airtight middle continuous stirring 10min of room temperature, last ultrasonic 5min, after the 0.22 μ m microporous filter membrane aseptic filtration of footpath, obtain colourless translucent praeruptorin A microemulsion.
Embodiment 3 microemulsion, its formula is composed as follows:
Preparation method: will refine Oleum Camelliae, tween, glycerol mix homogeneously and obtain oil phase, praeruptorin A is added in oil phase and dissolved completely; The oil phase that contains praeruptorin A is at room temperature stirred to 10min and make it mix homogeneously, gradually water is added again, at the airtight middle continuous stirring 10min of room temperature, last ultrasonic 5min, after the 0.22 μ m microporous filter membrane aseptic filtration of footpath, obtain colourless translucent praeruptorin A microemulsion.
Embodiment 4 microemulsion, its formula is composed as follows:
Preparation method: olive oil, phospholipid of natural soybean, Polyethylene Glycol mix homogeneously are obtained to oil phase, praeruptorin A is added in oil phase and dissolved completely; The oil phase that contains praeruptorin A is at room temperature stirred to 10min and make it mix homogeneously, gradually water is added again, at the airtight middle continuous stirring 10min of room temperature, last ultrasonic 5min, after the 0.22 μ m microporous filter membrane aseptic filtration of footpath, obtain colourless translucent praeruptorin A microemulsion.
Preparation method: isopropyl palmitate, polyoxyethylene hydrogenated Oleum Ricini (Cremophor RH40), dehydrated alcohol mix homogeneously are obtained to oil phase, praeruptorin A is added in oil phase and dissolved completely; The oil phase that contains praeruptorin A is at room temperature stirred to 10min and make it mix homogeneously, gradually water is added again, at the airtight middle continuous stirring 10min of room temperature, last ultrasonic 5min, after the 0.22 μ m microporous filter membrane aseptic filtration of footpath, obtain colourless translucent praeruptorin A microemulsion.
Below provide external quality evaluation:
1. permeation test in vitro
Get the male SD rat of body weight 200～250g, after etherization, with electric shaver, shave clean abdominal part chaeta, get not damaged skin, carefully reject subcutaneous fat and adhesion thing, with normal saline flushing skin surfaces externally and internally, after-20 ℃ of preservation 12h, use, before using, naturally thaw.The Franz diffusion cell that has adopted improvement, is fixed on skin between upper and lower two Room of diffusion cell, and stratum corneum side is to supply pool, and acceptance pool adds 33% ethanol/normal saline, and (acceptance pool volume is 6.5mL, and transmission area is 2.8cm
2), in supply chamber, add medicinal liquid 0.7g, device is placed in to constant temperature (37 ± 0.5 ℃) water-bath, start stirring (210rmin
-1), respectively at 1,2,4,6,8,12,24,28,32h samples 2mL, adds the fresh accepting medium of uniform temp equal-volume simultaneously.After sample is centrifugal, then use 0.22 μ m filtering with microporous membrane, sample thief subsequent filtrate 20 μ L carry out HPLC analysis.
In praeruptorin A microemulsion formula prepared by the present invention, containing Pd-Ia, be 0.5%, result shows, embodiment 1 is optimization formula, and it is that surfactant, 26.67% ethanol are cosurfactant, 52.5% ultra-pure water as oil phase, 13.33% polyoxyethylene hydrogenated Oleum Ricini that the composition of formula is respectively 5% oleic acid.Preparation is carried out transdermal permeation in vitro containing the optimum microemulsion of 0.5% praeruptorin A, and obtaining maximum transdermal penetration speed is 11.713 ± 0.513 μ gcm
-2h
-1, 32h transdermal penetration total amount is 353.266 ± 13.584 μ gcm
-2, there is good percutaneous permeation.The results are shown in Table 1 and Fig. 1.
The comparison (n=5) of the in-vitro percutaneous absorption of Pd-Ia microemulsion of the different embodiment of table 1
2. external physicochemical property
Shape, the particle diameter of measuring the Pd-Ia microemulsion of above-mentioned preparation, the results are shown in Table 2.
Shape, the size of table 2Pd-Ia microemulsion
Select optimum example, embodiment 1 observes the form of Pd-Ia microemulsion under transmission electron microscope, and the TEM figure of shooting, is shown in Fig. 2, by Electronic Speculum, can find that the emulsion droplet in Pd-Ia microemulsion is spherical in shape, form rounding, and particle diameter is distributed in 100nm mostly.
3. stability test
0,3,6 month precision, take a certain amount of enforcement 1 microemulsion sample in the volumetric flask of 10mL respectively, add appropriate methanol vortex 2min, ultrasonic 5min and carry out breakdown of emulsion, then use methanol constant volume.Sample thief is appropriate, after filtering, gets subsequent filtrate 20 μ L with 0.45 μ m microporous filter membrane, by HPLC method, surveys its content.The results are shown in Table 3.As can be known from the results, 5.0mgg
-1pd-Ia microemulsion sample is placed after 6 months in room temperature, and medicament contg RSD% is 2.11%, without significant change, illustrates that at room temperature Pd-Ia microemulsion is stable.
Table 3 is containing the content (n=3) of 0.5%Pd-Ia microemulsion sample
4. particle diameter and microscopic pattern
By aforementioned optimization of C/C composites and preparation method, preparation 4.88mgg
-1pd-Ia microemulsion sample, is divided in three batch samples in cillin bottle, packs, room temperature preservation, standby.At 0,3,6 month, get respectively appropriate sample, centrifugal rear observation outward appearance, measures size and distribution, in Table 4, Fig. 3 and 4.As can be known from the results, Pd-Ia microemulsion is after room temperature is placed 3,6 months, and color and luster, clarity do not become, and without layering, flocculation phenomenon, outward appearance is unchanged, still keeps transparent, clarification after centrifugal.Before and after placing, particle diameter is without significant change.
Table 4 is containing the particle diameter (n=3) of 0.5%Pd-Ia microemulsion sample
The form of microemulsion particle: at 0,6 month, get respectively the Pd-Ia microemulsion sample that above-mentioned sealing is preserved, the form of observing microemulsion under transmission electron microscope, the TEM figure of shooting, is shown in Fig. 3 and 4.As we know from the figure, Pd-Ia microemulsion is preserved 6 months, electric Microscopic observation droplet morphology rounding, and particle diameter is in 100nm, and microscopic pattern is without obvious variation.
Claims (9)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310726365.8A CN103690483A (en) | 2013-12-25 | 2013-12-25 | Dl-praeruptorin A microemulsion and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310726365.8A CN103690483A (en) | 2013-12-25 | 2013-12-25 | Dl-praeruptorin A microemulsion and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103690483A true CN103690483A (en) | 2014-04-02 |
Family
ID=50352258
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310726365.8A Pending CN103690483A (en) | 2013-12-25 | 2013-12-25 | Dl-praeruptorin A microemulsion and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103690483A (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106109413A (en) * | 2016-07-29 | 2016-11-16 | 河南中医学院 | A kind of oil-in-water type nano-emulsion substrate |
| CN107318981A (en) * | 2017-06-19 | 2017-11-07 | 宁国市仙之居家庭农场 | A kind of Yoghourt based on the peaceful root of purple-flowered peucedanum |
| CN109744325A (en) * | 2019-03-06 | 2019-05-14 | 吉林大学 | A kind of nanoemulsion system and preparation method based on perilla oil or linseed oil |
| CN110420183A (en) * | 2019-09-04 | 2019-11-08 | 湖南宇山玉月农业科技有限公司 | A kind of schizophyllum abamectin nano-emulsion |
| CN111920766A (en) * | 2020-07-28 | 2020-11-13 | 中南林业科技大学 | A kind of ellagic acid dispersion system and preparation method thereof |
| CN112972368A (en) * | 2021-04-19 | 2021-06-18 | 哈尔滨医科大学 | Pharmaceutical composition for promoting healing of postoperative wound surface of anorectal surgery and preparation method thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101759705A (en) * | 2009-10-22 | 2010-06-30 | 南京泽朗医药科技有限公司 | Method for preparing praeruptorin A |
| CN102771853A (en) * | 2012-05-09 | 2012-11-14 | 操应胜 | Peucedanum praeruptorum dunn beverage, peucedanum praeruptorum dunn beverage health-care product and production process thereof |
-
2013
- 2013-12-25 CN CN201310726365.8A patent/CN103690483A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101759705A (en) * | 2009-10-22 | 2010-06-30 | 南京泽朗医药科技有限公司 | Method for preparing praeruptorin A |
| CN102771853A (en) * | 2012-05-09 | 2012-11-14 | 操应胜 | Peucedanum praeruptorum dunn beverage, peucedanum praeruptorum dunn beverage health-care product and production process thereof |
Non-Patent Citations (1)
| Title |
|---|
| 张贤华: "白花前胡甲素微乳凝胶的研究", 《硕士学位论文》 * |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106109413A (en) * | 2016-07-29 | 2016-11-16 | 河南中医学院 | A kind of oil-in-water type nano-emulsion substrate |
| CN106109413B (en) * | 2016-07-29 | 2019-04-16 | 河南中医学院 | A kind of oil-in-water type nano-emulsion matrix |
| CN107318981A (en) * | 2017-06-19 | 2017-11-07 | 宁国市仙之居家庭农场 | A kind of Yoghourt based on the peaceful root of purple-flowered peucedanum |
| CN109744325A (en) * | 2019-03-06 | 2019-05-14 | 吉林大学 | A kind of nanoemulsion system and preparation method based on perilla oil or linseed oil |
| CN110420183A (en) * | 2019-09-04 | 2019-11-08 | 湖南宇山玉月农业科技有限公司 | A kind of schizophyllum abamectin nano-emulsion |
| CN110420183B (en) * | 2019-09-04 | 2021-09-21 | 湖南宇山玉月农业科技有限公司 | Schizophyllan nanoemulsion |
| CN111920766A (en) * | 2020-07-28 | 2020-11-13 | 中南林业科技大学 | A kind of ellagic acid dispersion system and preparation method thereof |
| CN112972368A (en) * | 2021-04-19 | 2021-06-18 | 哈尔滨医科大学 | Pharmaceutical composition for promoting healing of postoperative wound surface of anorectal surgery and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kogan et al. | Microemulsions as transdermal drug delivery vehicles | |
| CN103690483A (en) | Dl-praeruptorin A microemulsion and preparation method thereof | |
| CN101366697A (en) | Novel nano-lipid carrier for injection embodying paclitaxel series substances and preparation method thereof | |
| CN103520006A (en) | Flexible nano liposome as well as preparation method and application of flexible nano liposome | |
| Date et al. | Microemulsions: applications in transdermal and dermal delivery | |
| CN102462723B (en) | Tripterygium glycoside-containing micro-emulsified gel transdermal preparation and preparation method thereof | |
| CN101675917A (en) | Propofol self-micro-emulsifying composition and preparation method thereof | |
| CN102048688B (en) | Paclitaxel Submicroemulsion Using Cholesterol Complex as Intermediate Carrier | |
| CN102159187A (en) | Vinca alkaloid nanoemulsion injection and preparation method thereof | |
| CN111195230B (en) | Method for preparing flexible liposome | |
| CN101428002A (en) | Paclitaxel freeze drying microemulsion for injection and method of producing the same | |
| CN101427993A (en) | Prostaglandin microemulsion gel rubber preparation and method of producing the same | |
| JP5531230B2 (en) | Oily external preparation and method for producing the same | |
| CN108159055A (en) | Treat long-acting delivery system, preparation method and the application of breast cancer | |
| CN101396344A (en) | Paeonol microemulsion preparation and preparation method thereof | |
| CN104474551B (en) | Melatonin phosphatide complexes, its Percutaneously administrable preparation and preparation method thereof | |
| CN104688721A (en) | Anti-rheumatoid arthritis drug gel containing paclitaxel liposome and preparation method of gel | |
| CN105147689A (en) | Compound antimalarial composition | |
| CN119925273A (en) | A nano lipid mass transfer body for efficiently loading plant active ingredients and its preparation method and application | |
| CN104173285A (en) | Preparation method for triamcinolone acetonide acetate ultradeformable nanometer lipid vesicle spraying agent and application to target hypertrophic scars | |
| KR20050105445A (en) | Asiaticoside-liposome and its use | |
| CN114452255A (en) | Agomelatine microemulsion, microemulsion gel and preparation method thereof | |
| CN101416963A (en) | Nimodipine freeze-drying sub micellar emulsion for injection and preparation method thereof | |
| WO2025020618A1 (en) | Soluble microneedle containing cannabidiol suspension and preparation method therefor | |
| CN101125145A (en) | Local using prostaglandin micro emulsion and its preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20140402 |